Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results and Host Conference Call on March 23, 2010

POINT RICHMOND, Calif., March 9 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it plans to release fourth quarter and full year 2009 financial results on March 23, 2010 after the close of the market.  At 5:00 p.m. Eastern Time, Transcept management will host a webcast and teleconference to discuss these results.  

Conference Call Information

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website beginning shortly after the conclusion of the call through April 23, 2010.

A telephone replay of the conference call will be available beginning shortly after the conclusion of the call through April 23, 2010.  The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 60018524.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience.  The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter.  Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  For further information, please visit the company's website at: www.transcept.com.

SOURCE Transcept Pharmaceuticals, Inc.